(1.02%) 5 099.96 points
(0.40%) 38 240 points
(2.03%) 15 928 points
(0.11%) $83.66
(-3.32%) $1.920
(0.30%) $2 349.60
(-0.43%) $27.52
(0.42%) $924.40
(0.32%) $0.935
(0.67%) $11.02
(0.13%) $0.800
(-0.07%) $92.11
Live Chart Being Loaded With Signals
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial...
Stats | |
---|---|
Šios dienos apimtis | 31.00 |
Vidutinė apimtis | 42.00 |
Rinkos kapitalizacija | 3.37B |
EPS | $24.13 ( 2023-11-06 ) |
Last Dividend | $0.121 ( 2023-03-30 ) |
Next Dividend | $0 ( N/A ) |
P/E | 19.29 |
ATR14 | $0 (0.00%) |
Santen Pharmaceutical Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Santen Pharmaceutical Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $279.04B |
Bruto pelnas: | $166.09B (59.52 %) |
EPS: | $-38.58 |
FY | 2023 |
Pajamos: | $279.04B |
Bruto pelnas: | $166.09B (59.52 %) |
EPS: | $-38.58 |
FY | 2022 |
Pajamos: | $266.26B |
Bruto pelnas: | $156.59B (58.81 %) |
EPS: | $68.07 |
FY | 2021 |
Pajamos: | $249.61B |
Bruto pelnas: | $151.38B (60.65 %) |
EPS: | $17.09 |
Financial Reports:
No articles found.
Santen Pharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0.111 (N/A) |
$0 (N/A) |
$0.121 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.0980 | 2014-03-27 |
Last Dividend | $0.121 | 2023-03-30 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 18 | -- |
Total Paid Out | $2.40 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 3.08 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 4.85 | |
Div. Directional Score | 7.99 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
NCBDF | Ex Dividend Junior | 2023-09-28 | Annually | 0 | 0.00% | |
CRHKY | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
TBLMY | Ex Dividend Junior | 2023-07-06 | Annually | 0 | 0.00% | |
HRST | Ex Dividend Junior | 2023-06-22 | Semi-Annually | 0 | 0.00% | |
AXAHY | Ex Dividend Junior | 2023-05-04 | Annually | 0 | 0.00% | |
PCLB | Ex Dividend Knight | 2023-09-01 | Quarterly | 0 | 0.00% | |
DWNX | Ex Dividend Knight | 2023-09-28 | Quarterly | 0 | 0.00% | |
TYFG | Ex Dividend Junior | 2023-09-28 | Quarterly | 0 | 0.00% | |
JRONY | Ex Dividend Knight | 2023-05-15 | Annually | 0 | 0.00% | |
BPOSY | Ex Dividend Knight | 2023-05-18 | Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0918 | 1.500 | 8.16 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0648 | 1.200 | 7.84 | 9.41 | [0 - 0.3] |
returnOnEquityTTM | 0.0924 | 1.500 | -0.0848 | -0.127 | [0.1 - 1] |
payoutRatioTTM | 0.429 | -1.000 | 5.71 | -5.71 | [0 - 1] |
currentRatioTTM | 2.46 | 0.800 | 2.72 | 2.17 | [1 - 3] |
quickRatioTTM | 1.841 | 0.800 | 3.88 | 3.10 | [0.8 - 2.5] |
cashRatioTTM | 0.897 | 1.500 | 6.13 | 9.19 | [0.2 - 2] |
debtRatioTTM | 0.0786 | -1.500 | 8.69 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 20.13 | 1.000 | 3.66 | 3.66 | [3 - 30] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.113 | -1.500 | 9.55 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.606 | 1.000 | 3.24 | 3.24 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.143 | 1.000 | 9.14 | 9.14 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 2.03 | 1.000 | 10.00 | 10.00 | [0.2 - 2] |
assetTurnoverTTM | 0.706 | 0.800 | 8.63 | 6.90 | [0.5 - 2] |
Total Score | 11.14 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 18.69 | 1.000 | 8.21 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0924 | 2.50 | -0.0545 | -0.127 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 162.21 | 2.00 | 10.00 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 0.0150 | 1.500 | 9.63 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 192.60 | 2.00 | 10.00 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.429 | 1.500 | 5.71 | -5.71 | [0 - 1] |
pegRatioTTM | -0.000754 | 1.500 | -3.34 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.225 | 1.000 | 6.86 | 0 | [0.1 - 0.5] |
Total Score | 4.85 |
Santen Pharmaceutical
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-111, which is in Phase III clinical trial; DE-117 in Japan; DE-126 that is in Phase IIb clinical trial; DE-128 in Europe, as well as is in Phase II/III clinical trial in the United States; and DE-130A that is in Phase III clinical trial. In addition, the company provides DE-114A to treat allergic conjunctivitis; DE-076C for the treatment of vernal keratoconjunctivitis; and DE-109, which is in Phase III clinical trial to treat uveitis. Further, it offers DE-127 to treat myopia, which is in Phase II/III clinical trial in Japan, as well as is in Phase III in Asia; DE-089C, which has completed Phase III clinical trials for the treatment of dry eye; and STN1013400, which is in Phase I clinical trials for the treatment of myopia. Additionally, the company offers over-the-counter pharmaceutical products. The company was formerly known as Santendo Pharmaceutical Co., Ltd. and changed its name to Santen Pharmaceutical Co., Ltd. in 1958. Santen Pharmaceutical Co., Ltd. was founded in 1890 and is headquartered in Osaka, Japan.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.